Abstract
In bacterial type II fatty acid biosynthesis (FAS-II), β-ketoacyl-acyl carrier protein (ACP) synthase III (FabH) initiates the first condensation of acyl-CoA and malonyl-ACP to form acetoacetyl-ACP. Its key role for organism survival and specificity to bacteria make it as an essential target for the discovery of novel antibacterial agents. Over the last decade, several structures of FabH from diverse microorganisms have been solved, giving detailed information about the three-dimensional features of the catalytic pocket. This has facilitated the rational design of FabH inhibitors, which provides a framework for future development of antibiotics against multi-drug resistant strains. This review covers recent advances in the biochemical and structural research of FabH and updates the main families of related inhibitors.
Keywords: Antibacterial, active site, β-Ketoacyl-acyl carrier protein synthase III (FabH), inhibitors, type II fatty acid biosynthesis (FAS-II).
Current Medicinal Chemistry
Title:Bacterial β-Ketoacyl-Acyl Carrier Protein Synthase III (FabH) as a Target for Novel Antibacterial Agents Design
Volume: 22 Issue: 5
Author(s): X.Y. Lu, J. Tang, Z. Zhang and K. Ding
Affiliation:
Keywords: Antibacterial, active site, β-Ketoacyl-acyl carrier protein synthase III (FabH), inhibitors, type II fatty acid biosynthesis (FAS-II).
Abstract: In bacterial type II fatty acid biosynthesis (FAS-II), β-ketoacyl-acyl carrier protein (ACP) synthase III (FabH) initiates the first condensation of acyl-CoA and malonyl-ACP to form acetoacetyl-ACP. Its key role for organism survival and specificity to bacteria make it as an essential target for the discovery of novel antibacterial agents. Over the last decade, several structures of FabH from diverse microorganisms have been solved, giving detailed information about the three-dimensional features of the catalytic pocket. This has facilitated the rational design of FabH inhibitors, which provides a framework for future development of antibiotics against multi-drug resistant strains. This review covers recent advances in the biochemical and structural research of FabH and updates the main families of related inhibitors.
Export Options
About this article
Cite this article as:
Lu X.Y., Tang J., Zhang Z. and Ding K., Bacterial β-Ketoacyl-Acyl Carrier Protein Synthase III (FabH) as a Target for Novel Antibacterial Agents Design, Current Medicinal Chemistry 2015; 22 (5) . https://dx.doi.org/10.2174/0929867322666141212115236
DOI https://dx.doi.org/10.2174/0929867322666141212115236 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Peptide Biomarkers: Exploring the Diagnostic Aspect
Current Protein & Peptide Science An Acetylated Triterpene Glycoside and Lignans from <i>Phyllanthus myrtifolius</i> and their Antibacterial Activities
The Natural Products Journal Review of Methods and Various Catalysts Used for Chalcone Synthesis
Mini-Reviews in Organic Chemistry Enzymatic Activity and Protein Interactions in Alpha/Beta Hydrolase Fold Proteins: Moonlighting Versus Promiscuity
Protein & Peptide Letters Treatment of Opportunistic Infections Prior to HAART Initiation Does Not Affect Immune Reconstitution in HIV-Infected Patients
Current HIV Research Nitric Oxide Synthase (NOS) as Therapeutic Target for Asthma and Chronic Obstructive Pulmonary Disease
Current Drug Targets Natural T Cell Immunity to Intracellular Pathogens and Nonpeptidic Immunoregulatory Drugs
Current Molecular Medicine Nanobiotechnological Approaches Against Multidrug Resistant Bacterial Pathogens: An Update
Current Drug Metabolism Optimal Antibiotic Therapy in the Management of the Lung of the Critically Ill
Current Respiratory Medicine Reviews Crucial Enzymes in the Hydroxylated Triacylglycerol-ricinoleate Biosynthesis Pathway of Castor Bean
Current Protein & Peptide Science Targeting the Epidermal Growth Factor Receptor: Exploring the Potential of Novel Inhibitor N-(3-Ethynylphenyl)-6, 7-bis (2-methoxyethoxy) Quinolin- 4-Amine Using Docking and Molecular Dynamics Simulation
Protein & Peptide Letters Anti-Inflammatory Trends of 1, 3-Diphenyl-2-propen-1-one Derivatives
Mini-Reviews in Medicinal Chemistry Nanostructured Approaches for the Targeted Delivery of Antibiotics in Difficult Infections
Current Organic Chemistry Therapeutic Implications of Gene Deletion of Ligands and Receptors of Members of TNF Superfamily
Medicinal Chemistry Reviews - Online (Discontinued) Biocombinatorial Selection of Carbohydrate Binding Agents of Therapeutic Significance
Current Drug Discovery Technologies Potential of Nanocarriers in Genetic Immunization
Recent Patents on Drug Delivery & Formulation Bacterial Zinc Proteases and their Inhibition
Current Enzyme Inhibition Gold Nanoparticles - Synthesis and Applications in Cancer Management
Recent Patents on Materials Science New Approaches for the Treatment of Chagas Disease
Current Drug Targets Longitudinal Analysis of Adherence to First-Line Antiretroviral Therapy: Evidence of Treatment Sustainability from an Indian HIV Cohort
Current HIV Research